Accelerating Universal Access to Early and Effective Tuberculosis Care

Abstract*

The objective of the Accelerating Universal Access to Early and Effective Tuberculosis (TB) Care Project is to support the aims of India's national strategic plan for tuberculosis control to expand the provision and utilization of quality diagnosis and treatment services for people suffering from tuberculosis. There are three components to the project, the first component being new strategies to reach more tuberculosis patients with earlier and more... Show More

Development Objective

To support the aims of India's National Strategic Plan for Tuberculosis Control to expand the provision and utilization of quality diagnosis and treatment services for people suffering from tuberculosis.

Key Details

Project Details

Project ID
P148604
Status
Closed
Team Leader
Jorge Coarasa Bustamante
Borrower 2
Department of Economic Affairs, Ministry of Finance, Republic of India

Country
India
Disclosure Date
December 1, 2013
Approval Date
(as of board presentation)
April 8, 2014
Effective Date
June 26, 2014

Total Project Cost 1
US$ 532.00 million
Implementing Agency
Ministry of Health and Family Welfare
Region
South Asia
Fiscal Year 3
2014

Commitment Amount
US$ 197.00 million
Environmental Category
B
Environmental and Social Risk
Not Applicable
Closing Date
March 31, 2018

Consultant Services required
Yes
Last Stage Reached
BANK APPROVED
Last Update Date
September 14, 2023

Notes
1. Total project cost includes funding from World Bank and non-bank sources in US$ millions. Active and Closed projects show current commitments. Proposed (pipeline) and dropped projects show the forecast amount. The commitment amount for projects in the pipeline is indicative and may be modified during the project preparation.
2. Borrower refers to the Borrower of a Loan or Recipient of a Grant.
3. ”Fiscal Year” is the fiscal year in which the project was approved (or dropped if the status is dropped). The World Bank's fiscal year is from July 1 - June 30. For example, a fiscal year of 1996 corresponds to July 1, 1995 - June 30, 1996.

Sectors

Themes

FY17 - Human Development and Gender

FY17 - Disease Control50%
- FY17 - Tuberculosis50%
FY17 - Health Systems and Policies50%
- FY17 - Child Health10%
- FY17 - Health System Strengthening40%

Project Map

Interactive Map

Finances

Financing Plan (US$ Millions)

Financier	Commitments
Borrower/Recipient	335.00
The Global Fund to Fight AIDS, Tuberculosis & Malaria	97.00
IDA recommitted as a Credit	100.00

Total Project Financing (US$ Millions)

Product Line	IBRD/IDA
IBRD Commitment	N/A
IDA Commitment	100.00
IBRD + IDA Commitment	100.00

Lending Instrument
Grant Amount	97.00
Total Project Cost**	532.00

Summary Status of World Bank Financing (US$ Millions) as of April 30, 2025

No data available.

Detailed Financial Activity as of April 30, 2025

Download:

Period	Financier	Transaction Type	Amount (US$)
Mar 31, 2016	IDA-53760	Loan Disb	2,216,844.80
Feb 23, 2016	IDA-53760	Loan Disb	2,680,799.20
Sep 28, 2016	IDA-53760	Loan Disb	4,673,251.00
Apr 1, 2016	IDA-53760	Int Charges	293.38
Apr 1, 2016	IDA-53760	Int Charges	36,616.03
Apr 1, 2016	IDA-53760	Int Charges	36,616.03
Apr 1, 2016	IDA-53760	Int Charges	53,118.63
Dec 15, 2016	IDA-53760	Loan Disb	22,329,666.00
Oct 1, 2016	IDA-53760	Int Charges	53,890.24
Oct 1, 2016	IDA-53760	Int Charges	53,890.24
Oct 1, 2016	IDA-53760	Int Charges	89,161.03
Jan 11, 2017	IDA-53760	Loan Disb	10,799,069.00
Dec 9, 2016	IDA-53760	Loan Disb	8,804,152.00
Oct 1, 2016	IDA-53760	Int Charges	7,833.37
Apr 1, 2017	IDA-53760	Int Charges	637.75
Apr 1, 2017	IDA-53760	Int Charges	126,288.73
Apr 1, 2017	IDA-53760	Int Charges	126,288.73
Apr 1, 2017	IDA-53760	Int Charges	31,885.05
Apr 1, 2017	IDA-53760	Int Charges	31,885.05
Apr 1, 2017	IDA-53760	Int Charges	263,622.97
Mar 20, 2017	IDA-53760	Loan Disb	1,337,991.60
Oct 1, 2017	IDA-53760	Int Charges	403,872.30
Oct 1, 2017	IDA-53760	Int Charges	241,611.80
Oct 1, 2017	IDA-53760	Int Charges	241,611.80
Oct 1, 2017	IDA-53760	Int Charges	1,090.76
Oct 1, 2017	IDA-53760	Int Charges	1,090.76
Oct 1, 2023	IDA-53760	Loan Repay	2,803,672.50
Apr 1, 2024	IDA-53760	Loan Repay	65,937.58
Apr 1, 2024	IDA-53760	Int Charges	248,115.50
Apr 1, 2024	IDA-53760	Int Charges	248,115.50
Apr 1, 2024	IDA-53760	Int Charges	413,525.90
Apr 1, 2024	IDA-53760	Loan Repay	2,773,356.00
Apr 8, 2014	IDA-53760	Loan Commitment	100,000,000.00
Oct 1, 2022	IDA-53760	Loan Repay	28,961.74
Oct 1, 2022	IDA-53760	Loan Repay	2,716,380.80
Oct 1, 2022	IDA-53760	Int Charges	270,790.62
Oct 1, 2022	IDA-53760	Int Charges	270,790.62
Oct 1, 2022	IDA-53760	Int Charges	451,317.66
Apr 1, 2023	IDA-53760	Loan Repay	2,763,956.50
Apr 1, 2023	IDA-53760	Int Charges	273,796.30
Apr 1, 2023	IDA-53760	Int Charges	273,796.30
Apr 1, 2023	IDA-53760	Int Charges	456,327.25
Apr 1, 2023	IDA-53760	Loan Repay	121,561.82
Oct 1, 2023	IDA-53760	Loan Repay	16,959.72
Oct 1, 2023	IDA-53760	Int Charges	257,062.16
Oct 1, 2023	IDA-53760	Int Charges	257,062.16
Oct 1, 2023	IDA-53760	Int Charges	428,436.88
Apr 1, 2021	IDA-53760	Int Charges	528,023.00
Apr 1, 2021	IDA-53760	Loan Repay	4,253.00
Apr 1, 2021	IDA-53760	Loan Repay	1,515,072.00
Apr 1, 2021	IDA-53760	Int Charges	316,813.80
Apr 1, 2021	IDA-53760	Int Charges	316,813.80
Oct 1, 2021	IDA-53760	Loan Repay	1,477,845.60
Oct 1, 2021	IDA-53760	Int Charges	310,031.34
Oct 1, 2021	IDA-53760	Int Charges	310,031.34
Oct 1, 2021	IDA-53760	Int Charges	516,719.00
Oct 1, 2021	IDA-53760	Loan Repay	36,181.20
Apr 1, 2022	IDA-53760	Loan Repay	28,337.77
Apr 1, 2022	IDA-53760	Loan Repay	1,452,119.80
Apr 1, 2022	IDA-53760	Int Charges	297,605.60
Apr 1, 2022	IDA-53760	Int Charges	297,605.60
Apr 1, 2022	IDA-53760	Int Charges	496,009.34
Oct 1, 2019	IDA-53760	Loan Repay	2,914,838.00
Oct 1, 2019	IDA-53760	Loan Repay	6,695.00
Oct 1, 2019	IDA-53760	Int Charges	331,992.38
Oct 1, 2019	IDA-53760	Int Charges	331,992.38
Oct 1, 2019	IDA-53760	Int Charges	553,320.60
Apr 1, 2020	IDA-53760	Loan Repay	21,269.94
Apr 1, 2020	IDA-53760	Loan Repay	2,908,607.00
Apr 1, 2020	IDA-53760	Int Charges	0.01
Apr 1, 2020	IDA-53760	Int Charges	0.01
Apr 1, 2020	IDA-53760	Int Charges	321,953.47
Oct 1, 2018	IDA-53760	Int Charges	338,164.72
Oct 1, 2018	IDA-53760	Int Charges	565,015.50
Apr 1, 2019	IDA-53760	Int Charges	4,741.05
Apr 1, 2019	IDA-53760	Int Charges	4,741.05
Apr 1, 2019	IDA-53760	Int Charges	333,620.53
Apr 1, 2019	IDA-53760	Int Charges	333,620.53
Apr 1, 2019	IDA-53760	Int Charges	563,935.94
Apr 1, 2015	IDA-53760	Int Charges	2,023.80
Apr 1, 2015	IDA-53760	Int Charges	2,023.80
Feb 12, 2015	IDA-53760	Loan Disb	2,400,862.50
Feb 10, 2015	IDA-53760	Loan Disb	1,839,718.80
Dec 1, 2014	IDA-53760	Loan Disb	315,142.25
Oct 1, 2015	IDA-53760	Int Charges	3,076.69
Oct 1, 2015	IDA-53760	Int Charges	3,076.69
Oct 1, 2015	IDA-53760	Int Charges	8,551.08
Oct 1, 2015	IDA-53760	Int Charges	22,928.34
Oct 1, 2015	IDA-53760	Int Charges	22,928.34
Oct 1, 2015	IDA-53760	Int Charges	37,922.38
Oct 22, 2015	IDA-53760	Loan Disb	2,708,864.80
May 22, 2015	IDA-53760	Loan Disb	2,242,968.50
Apr 1, 2020	IDA-53760	Int Charges	321,953.47
Apr 1, 2020	IDA-53760	Int Charges	536,589.25
Oct 1, 2020	IDA-53760	Loan Repay	1,482,162.80
Oct 1, 2020	IDA-53760	Loan Repay	30,620.01
Oct 1, 2020	IDA-53760	Int Charges	321,122.50
Oct 1, 2020	IDA-53760	Int Charges	321,122.50
Oct 1, 2020	IDA-53760	Int Charges	535,204.10
Apr 1, 2018	IDA-53760	Int Charges	650.08
Apr 1, 2018	IDA-53760	Int Charges	137,228.28
Apr 1, 2018	IDA-53760	Int Charges	137,228.28
Apr 1, 2018	IDA-53760	Int Charges	145,032.89
Apr 1, 2018	IDA-53760	Int Charges	145,032.89
Apr 1, 2018	IDA-53760	Int Charges	470,435.25
Apr 6, 2018	IDA-53760	Loan Disb	12,072,383.00
Dec 22, 2017	IDA-53760	Loan Disb	15,388,259.00
Oct 1, 2018	IDA-53760	Int Charges	844.61
Oct 1, 2018	IDA-53760	Int Charges	844.61
Oct 1, 2018	IDA-53760	Int Charges	338,164.72

Footnotes

Ratings

IMPLEMENTATION RATINGS

Name	Review	Date
Procurement	Satisfactory	2018-04-03
Progress towards achievement of PDO	Satisfactory	2018-04-03
Financial Management	Satisfactory	2018-04-03
Monitoring and Evaluation	Satisfactory	2018-04-03
Overall Implementation Progress (IP)	Satisfactory	2018-04-03
Counterpart Funding	Satisfactory	2018-04-03
Project Management	Satisfactory	2018-04-03

COMPLETION RATINGS

INDICATOR	IMPLEMENTATION COMPLETION & RESULTS REPORT: 09-26-2018
Outcomes	Substantial
Risk to Development Outcome
Bank Performance	Substantial
Borrower Performance
Government Performance
Implementing Agency

INDEPENDENT EVALUATION RATINGS

INDICATOR	ICR REVIEW: 01-23-2019	PROJECT PERFORMANCE ASSESSMENT REPORT:
Outcome Rating	Satisfactory	N/a
Risk To Development Outcome		N/a
Bank Performance	Moderately Satisfactory	N/a
Borrower Performance		N/a
Government Performance	Not Rated	N/a
Implementing Agency		N/a
Icr Quality	High	N/a
M&e Quality	Substantial	N/a

Results Framework

PROJECT DEVELOPMENT OBJECTIVE INDICATORS

INDICATOR		BASELINE	CURRENT	TARGET

Direct project beneficiaries Value 0.00 6200000.00 6200000.00
Date January 1, 2014 December 31, 2017 December 31, 2017
Comment

People receiving tuberculosis treatment in accordance with the WHO-recommended “Directly Observed Treatment Strategy” (DOTS) (number)	Value	0.00	6200000.00	6430000.00
	Date	January 1, 2014	December 31, 2017	December 31, 2017
	Comment

Number of TB cases receiving care within public sector through daily regimen fixed drug combination Value 0.00 300000.00
Date January 1, 2016 December 31, 2017
Comment
Drug-resistant TB patients who have initiated treatment Value 25000.00 50000.00 38363.00
Date December 31, 2012 December 31, 2017 December 31, 2017
Comment
TB suspects and patients who have received drug-sensitivity testing (DST) Value 130244.00 246000.00 711125.00
Date December 31, 2012 December 31, 2017 December 31, 2017
Comment
Female beneficiaries Value 33.00 37.00 37.00
Date January 1, 2014 December 31, 2017 December 31, 2017
Comment
of which female Value 0.00 2294000.00 2294000.00
Date January 1, 2014 December 31, 2017 December 31, 2017
Comment
of which female Value 6000.00 14000.00 12851.00
Date December 31, 2012 December 31, 2017 December 31, 2017
Comment

INTERMEDIATE RESULTS INDICATORS

INDICATOR		BASELINE	CURRENT	TARGET

Percentage of patients with drug sensitive TB successfully completing treatment with daily regimen of fixed drug combination Value 0.00 81.00
Date January 1, 2016 December 31, 2017
Comment
Districts using locally installed CBNAAT machines for drug susceptibility testing Value 70.00 350.00 594.00
Date December 31, 2012 December 31, 2017 December 31, 2017
Comment
Drug-resistant TB patients who have completed treatment Value 48.00 57.00 47.00
Date December 31, 2012 December 31, 2017 December 31, 2017
Comment
Months between start of financial year and release to the states of funds for TB program implementation (average) Value 5.00 3.00 4.52
Date December 31, 2012 December 31, 2017 December 31, 2017
Comment
Pediatric TB cases initiated on treatment in the public sector Value 81000.00 100000.00 92308.00
Date December 31, 2012 December 31, 2017 December 31, 2017
Comment
Number of TB-HIV patients initiated on INH therapy in public sector Value 0.00 265256.00
Date January 1, 2016 December 31, 2017
Comment
Number of laboratories using e-Nikshay for surveillance of drug resistant patients Value 0.00 71.00
Date December 31, 2015 December 31, 2017
Comment
e-Nikshay module for expenditure tracking implemented in 2 States Value No Yes
Date January 1, 2016 December 31, 2017
Comment
e-Nikshay module on drug logistics rolled out in two states Value No Yes
Date January 1, 2016 December 31, 2017
Comment

Direct project beneficiaries	Value	0.00	6200000.00	6200000.00
	Date	January 1, 2014	December 31, 2017	December 31, 2017
	Comment

Drug-resistant TB patients who have initiated treatment	Value	25000.00	50000.00	38363.00
	Date	December 31, 2012	December 31, 2017	December 31, 2017
	Comment

TB suspects and patients who have received drug-sensitivity testing (DST)	Value	130244.00	246000.00	711125.00
	Date	December 31, 2012	December 31, 2017	December 31, 2017
	Comment

Female beneficiaries	Value	33.00	37.00	37.00
	Date	January 1, 2014	December 31, 2017	December 31, 2017
	Comment

of which female	Value	0.00	2294000.00	2294000.00
	Date	January 1, 2014	December 31, 2017	December 31, 2017
	Comment

of which female	Value	6000.00	14000.00	12851.00
	Date	December 31, 2012	December 31, 2017	December 31, 2017
	Comment

Districts using locally installed CBNAAT machines for drug susceptibility testing	Value	70.00	350.00	594.00
	Date	December 31, 2012	December 31, 2017	December 31, 2017
	Comment

Drug-resistant TB patients who have completed treatment	Value	48.00	57.00	47.00
	Date	December 31, 2012	December 31, 2017	December 31, 2017
	Comment

Months between start of financial year and release to the states of funds for TB program implementation (average)	Value	5.00	3.00	4.52
	Date	December 31, 2012	December 31, 2017	December 31, 2017
	Comment

Pediatric TB cases initiated on treatment in the public sector	Value	81000.00	100000.00	92308.00
	Date	December 31, 2012	December 31, 2017	December 31, 2017
	Comment